JAMA Network
About The Study: In this prespecified secondary analysis of the Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) prospective randomized trial, the overall lived experience of women randomized to undergo active monitoring for low-risk ductal carcinoma in situ was similar to that of women randomized to guideline-concordant care during the 2 years following diagnosis.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
